TB Online is no longer maintained. This is an archive of the site. For news on TB please go to: https://globaltbcab.org/

Items tagged with Scientific research

Can drug-resistant TB be reversed with a novel small molecule? Scientists turn to an animal model to find out (post)

Tuberculosis is a major public health concern, an ancient bacterial disease that has claimed the lives of kings, presidents, poets and at least one star of Hollywood's silver screen-era. Yet even now in the 21st century, it's still impossible to shake the scourge. TB kills someone around the globe every 22 seconds, the World Health Organization estimates.

Hundreds of new drug targets to combat TB (post)

Tuberculosis is a stubborn disease, born of yet more stubborn microbes. While many bacterial infections resolve within days of starting antibiotics, tuberculosis often refuses to budge for around six months and, in some cases, may never release its vice grip on the human body. It claimed 1.5 million lives in 2020, second only to COVID-19 among infectious diseases. 

New antibiotics could tackle drug-resistant TB (post)

Infection by Mycobacterium tuberculosis kills 1.5 million people worldwide every year. Antibiotics to treat TB exist, but in recent years, multi-drug resistant (MDR), extensively drug-resistant (XDR) and totally drug-resistant (TDR) strains of the bacterium have developed. According to a new study publishing May 31st in the open-access journal PLOS Biology by Ho-Yeon Song of Soonchunhyang University in the Republic of Korea and colleagues, a new class of antibiotics is highly effective against drug-resistant tuberculosis. If validated in clinical trials, the new drug class would represent a major advance in the treatment of tuberculosis.

New TB drug combination trial – hope for shorter treatment (post)

The University of Cape Town’s Lung Institute is conducting a new trial involving BTZ-043 (benzothiazinone DprE1 blocker), a novel TB drug candidate. There are also plans to test BTZ-043 in combination with two other new TB drug candidates. If all goes well, the new drug regimen could reduce TB treatment from the current six months to four.

The intersection of SARS-CoV-2 with TB: It's complicated (post)

A new animal study found mice infected with Mycobacterium tuberculosis and SARS-CoV-2 had an interesting synergism, according to a poster presented at ASM Microbe 2022 (abstract 3696), in Washington, D.C.

Genetic mutations enable efficient evolution of TB-causing bacteria (post)

Jun 21, 2022: Researchers have identified how the bacterium that causes tuberculosis (TB) can evolve rapidly in response to new environments, says a study published today in eLife.

Pathway behind pathogenic mechanism of TB identified (post)

Reverse electron transport causes overproduction of mitochondrial reactive oxygen species, a key contributor to the aggravation of tuberculosis pathogenesis.

Aerosol-based TB vaccine begins human trials (post)

6 July 2022: The University of Oxford has begun recruiting for a Phase I trial with a tuberculosis vaccine in human volunteers at Oxford to develop a new way to test the efficacy of future TB vaccines – with the first volunteers being challenged today (Wednesday).

Discovering new treatments for TB (post)

Mycobacterium tuberculosis, the causative agent of tuberculosis, remains the leading cause of infectious disease worldwide, affecting approximately a quarter of the globe's population. Treatment of infections is problematic due to the emergence of drug-resistant strains; however, University of Oklahoma professor Helen Zgurskaya, an expert in antibiotic resistance, is leading research on new potential therapeutic treatments for the disease.

New antibiotic resistance genes identified in TB (post)

A massive analysis of more than 10,000 different Mycobacterium tuberculosis bacteria isolates from 23 countries has revealed new genes associated with resistance to 13 first- and second-line new and repurposed antibiotics. The work, carried out by Comprehensive Resistance Prediction for Tuberculosis: an International Consortium (CRyPTIC), is described in two new papers publishing August 11th in the open-access journal PLOS Biology.

Page 61 of 74 · Total posts: 0

←First 60 61 62 Last→